At Glenmark, we are focused on developing and marketing branded and generic formulations worldwide, and have done so in the Nordic region since 2017.
Our portfolio in the Nordics consists of products within different therapeutic areas, and our aim is to continuously launch new products, both well-known molecules as well as molecules recently coming off patent.
Our R&D centres are equipped to research on a variety of dosage forms such as oral solid dosages, semi-solids, parenteral and aerosols for various indications.
Quality is of paramount importance, and stringent checks go into every product we manufacture. Our principles of excellence and the emphasis to ensure a culture of uncompromising quality are widely acknowledged.
Glenmark has 15 manufacturing sites in 4 countries – in India, USA, Czech Republic and Argentina - ensuring a consistent supply of our products. Apart from own manufacturing facilities, Glenmark cooperates with a number of partners who support us in our mission of enriching lives of patients by offering them high-quality and affordable medication.